FLNA
Filana Therapeutics Inc
$0.91
0.07 (8.79%) Today
0.01 (1.06%) After-hours
— up— down
Market Cap
$41M-70.6%
Revenue (TTM)
$0
$0Net Income (TTM)
$-42,285,743
$-42,285,743EPS (TTM)
-0.88
-0.88Shares Out
48.31M
48.31MOpen
$0.85
$0.85Previous Close
$0.85
$0.85Day Range
$0.83 – $0.94
$0.83 – $0.9452-Week Range
$0.67 – $4.98
$0.67 – $4.98Beta
1.43
1.43Volume
1.20M
1.20MAvg Volume
1.46M
1.46MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout FLNA
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Related
News
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
Benzinga · 1w ago
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Yahoo · 1w ago
Filana Therapeutics shares are trading higher after the company announced that the FDA lifted the clinical hold on its investigational new drug application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.
Benzinga · 1w ago
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Benzinga · 1w ago